Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PositronPOSC +5.51%30 Debt-to-Equity is 1.35 as of Dec. 2025. GuruFocus rates POSC with a GF Score™ of 30/100 and a GF Value™ of $0.12 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Positron ranks worse than 89.79% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Positron's Debt-to-Equity or its related term are showing as below:
POSC'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.13 Med: -0.89 Max: 1.35
Current: 1.35
During the past 13 years, the highest Debt-to-Equity Ratio of Positron was 1.35. The lowest was -3.13. And the median was -0.89.
POSC's Debt-to-Equity is ranked worse than 89.79% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs POSC: 1.35
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Positron Debt-to-Equity Related Terms
Positron Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Positron's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
POSC vs MDAI, ECOR, COCH: Debt-to-Equity Comparison
For the Medical Devices subindustry, Positron's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Positron Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Positron's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Positron's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Positron (POSC) has a Debt-to-Equity of 1.35 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Positron and its competitors. According to the industry distribution chart, Positron ranks #633 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 89.8%.
Is Positron's Debt-to-Equity too high?
Positron's current Debt-to-Equity is 1.35. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Positron's value of 1.35 is 487% above this industry median. Based on the distribution chart, Positron ranks #633 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Positron has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Positron's Debt-to-Equity compare to MDAI and ECOR?
According to the Medical Devices & Instruments industry distribution chart, Positron ranks #633 out of 705 companies for Debt-to-Equity. This places Positron in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Positron's value of 1.35 is 487% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Positron's current Debt-to-Equity of 1.35 is 487% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Positron and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Positron's current Debt-to-Equity is 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Positron stock overvalued right now?
Based on GuruFocus' analysis, Positron (POSC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.12, compared to a current price of $1.76 — trading 1368.3% above its estimated fair value. The current Debt-to-Equity is 1.35 and 487% above the Medical Devices & Instruments industry median of 0.23. Positron's overall GF Score™ is 30/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Positron (POSC), the current Debt-to-Equity is 1.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Positron (POSC) Overvalued in 2026?
Based on GuruFocus' analysis, Positron stock appears to be overvalued.
The current stock price of $1.76 is trading 1368.3% above its estimated GF Value™ of $0.12.
GuruFocus considers Positron to be Significantly Overvalued.
Key valuation signals for POSC:
Debt-to-Equity: 1.35
GF Value™: $0.12 vs. price of $1.76 (1368.3% above fair value)
Industry Position: 487% above the Medical Devices & Instruments median (#633 of 705)
No single metric tells the full story. See the POSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Positron Corp is a medical technology company engaged in the co-development, manufacture, and sale of PET and PET-CT imaging systems, delivering high-performance, cost-effective molecular imaging solutions that empower healthcare providers to improve the diagnosis and treatment of cardiovascular disease and other critical conditions. By combining proprietary PET and PET-CT systems with comprehensive clinical and technical support, flexible financing, & a focus on operational efficiency, Positron makes advance diagnostic imaging more accessible & sustainable for hospitals, outpatient centers, & physician practices. The company focused on advancing positron emission tomography imaging through the development, manufacture, & commercialization of PET & PET-computed tomography imaging systems.
30GF Score
Get the complete analysis for POSC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POSC has been successfully added to your 
